Britain’s Clinigen Group has agreed to be bought by UK-based private-equity firm Triton Investment Management in a deal that values the pharmaceutical services firm at about 1.2 billion pounds ($1.6 billion), the companies said on Wednesday.
Last week, Clinigen had confirmed advanced talks with Triton over a possible deal as pressure built up on the company on reports of activist investor Elliott Management raising its stake to propose a break up of Clinigen.
Triton has offered 883 pence per share in cash, with shareholders also eligible to receive a previously declared final dividend of 5.46 pence per Clinigen Share, the companies said.
Read more/Source: Reuters
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.